# EDGAR Filing Document

**Accession Number:** 0001858703
**File Stem:** 0001104659-25-085576
**Filing Date:** 2025-8
**Character Count:** 10217
**Document Hash:** 6305af3f7b0b645def96fe9d78c9ebab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-085576.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0001104659-25-085576

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250829

**EFFECTIVENESS DATE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Blue Owl Capital Holdings LP
- **CENTRAL INDEX KEY:** 0001858703

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-21866
- **FILM NUMBER:** 251280341

**BUSINESS ADDRESS:**
- **STREET 1:** 399 PARK AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 212-287-6787

**MAIL ADDRESS:**
- **STREET 1:** 399 PARK AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001858703

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Blue Owl Capital Holdings LP

**Address:** 399 Park Avenue, New York, NY 10022

**Telephone number:** 212-419-3000

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-21866

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 8

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                         | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Aquestive Therapeutics, Inc   | 03843E104 | 06/11/2025     | To approve, on a non-binding basis, the compensation of our named executive officers.                                                                    | SECTION 14A SAY-ON-PAY VOTES |         920000 |                0 | FOR         |                                   920000 | FOR                         |  |
| Cullinan Therapeutics, Inc    | 230031106 | 06/12/2025     | Proposal to vote, on an advisory basis, to approve our named executive officer compensation.                                                             | SECTION 14A SAY-ON-PAY VOTES |        2435948 |                0 | FOR         |                                  2435948 | FOR                         |  |
| Cullinan Therapeutics, Inc    | 230031106 | 06/12/2025     | Proposal to vote, on an advisory basis, on the frequency of future advisory votes on our named executive officer compensation.                           | SECTION 14A SAY-ON-PAY VOTES |        2435948 |                0 | FOR         |                                  2435948 | FOR                         |  |
| Compass Pathways PLC          | 20451W101 | 06/12/2025     | To approve, on a non-binding basis, the compensation of the Company's named executive officers for the year ended December 31, 2024.                     | SECTION 14A SAY-ON-PAY VOTES |        1135828 |                0 | FOR         |                                  1135828 | FOR                         |  |
| Eyepoint Pharmaceuticals, Inc | 30233G209 | 06/18/2025     | To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.      | SECTION 14A SAY-ON-PAY VOTES |         797594 |                0 | FOR         |                                   797594 | FOR                         |  |
| Eyepoint Pharmaceuticals, Inc | 30233G209 | 06/18/2025     | To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers.                  | SECTION 14A SAY-ON-PAY VOTES |         797594 |                0 | FOR         |                                   797594 | FOR                         |  |
| Disc Medicine, Inc            | 254604101 | 06/11/2025     | To approve, on a non-binding, advisory basis, the compensation paid to the Company's executive officers.                                                 | SECTION 14A SAY-ON-PAY VOTES |         145260 |                0 | FOR         |                                   145260 | FOR                         |  |
| Disc Medicine, Inc            | 254604101 | 06/11/2025     | To recommend, by a non-binding advisory vote, the frequency of future advisory votes on the compensation paid to the Company's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |         145260 |                0 | FOR         |                                   145260 | FOR                         |  |
| Keros Therapeutics            | 492327101 | 04/07/2025     | To approve,on a non-advisory basis, the compensation of the Company's named executive officers as disclosed in the accompanying Proxy Statement          | SECTION 14A SAY-ON-PAY VOTES |         265999 |                0 | FOR         |                                   265999 | FOR                         |  |
| Larimar Therapeutics          | 517125100 | 05/13/2025     | Approval, on an advisory basis, of the Compensation of our Named Executive Officers in 2024                                                              | SECTION 14A SAY-ON-PAY VOTES |        4753040 |                0 | FOR         |                                  4753040 | FOR                         |  |
| Marker Therapeutics           | 57055L206 | 05/14/2025     | To approve, on an advisory basis, the compensation paid to the Company's named executive officers.                                                       | SECTION 14A SAY-ON-PAY VOTES |         554250 |                0 | FOR         |                                   554250 | FOR                         |  |
| Pliant Therapeutics, Inc      | 729139105 | 06/05/2025     | To approve, by non-binding advisory vote, the resolution approving Named Executive Officer compensation.                                                 | SECTION 14A SAY-ON-PAY VOTES |        2964337 |                0 | FOR         |                                  2964337 | FOR                         |  |
| Palvella Therapeutics, Inc    | 697947109 | 06/10/2025     | Approval, on an advisory basis, of the Compensation of the Company's named Executive Officers.                                                           | SECTION 14A SAY-ON-PAY VOTES |         140259 |                0 | FOR         |                                   140259 | FOR                         |  |
| Ultragenyx Pharmaceutical Inc | 90400D108 | 05/15/2025     | Advisory (non-binding) vote to approve the compensation of our named executive officers.                                                                 | SECTION 14A SAY-ON-PAY VOTES |         143238 |                0 | FOR         |                                   143238 | FOR                         |  |
| Repare Therapeutics Inc       | 760273102 | 06/17/2025     | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the accompanying proxy statement.                    | SECTION 14A SAY-ON-PAY VOTES |        3443659 |                0 | FOR         |                                  3443659 | FOR                         |  |
| Tango Therapeutics, Inc       | 87583x109 | 06/05/2025     | To approve, on a non-binding, advisory basis, the compensation of our executive officers.                                                                | SECTION 14A SAY-ON-PAY VOTES |        2146652 |                0 | FOR         |                                  2146652 | FOR                         |  |
| Tango Therapeutics, Inc       | 87583x109 | 06/05/2025     | Non-binding advisory vote, on the frequency of future non-binding, advisory votes on the compensation of our named executive officers.                   | SECTION 14A SAY-ON-PAY VOTES |        2146652 |                0 | FOR         |                                  2146652 | FOR                         |  |
| Verona Pharma PLC             | 925050106 | 04/24/2025     | Advisory Vote to Ratify Named Executive Officers' Compensation.                                                                                          | SECTION 14A SAY-ON-PAY VOTES |          18347 |                0 | AGAINST     |                                    18347 | AGAINST                     |  |
| ADC Therapeutics, Inc.        | H0036K147 | 06/03/2025     | Approving, on an advisory basis under U.S. law, the compensation paid to our named executive officers.                                                   | SECTION 14A SAY-ON-PAY VOTES |         733568 |                0 | ABSTAIN     |                                   733568 | AGAINST                     |  |

## N-PX: Signature Block

**Reporting Person:** Blue Owl Capital Holdings LP

**By (Signature):** /s/ Karen Hager

**By (Printed Signature):** /s/ Karen Hager

**By (Title):** Chief Compliance Officer

**Date:** 08/29/2025